Guidelines on the diagnosis and management of multiple myeloma 2005.
about
The Prevalence and Management of Multiple Myeloma-Induced Kidney Disease in ChinaPre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging.Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.Bortezomib: the evidence of its clinical impact in multiple myeloma.Trends in the incidence and survival of multiple myeloma in South East England 1985-2004EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantageInherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancerAutologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial clinical efficiency results.Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study.Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.85-year-old man with epistaxisThe evolving use of serum free light chain assays in haematology.Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Multiple myeloma presenting as acute renal failureInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Determination of intrarenal resistance index (RI) in patients with multiple myeloma.Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease.Percutaneous vertebroplasty at C2: case report of a patient with multiple myeloma and a literature review.Pancytopenia in Multiple Myeloma- An Enigma: Our Experience from Tertiary Care Hospital.Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized studyClinical and organizational factors in the initial evaluation of patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Bortezomib for multiple myeloma.Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agentsManagement of paraproteinaemia.Melphalan and its role in the management of patients with multiple myeloma.Immunodeficiency and immunotherapy in multiple myeloma.Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience.Solitary Extramedullary Plasmacytoma of the Maxillary Sinus, Progressing to Smoldering Multiple Myeloma with Multifocal Skeletal Involvement, which Resolved Completely Following Chemotherapy AloneElevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.Current trends in multiple myeloma management.Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case.Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen.Reporting of quantitative protein electrophoresis in Australia and New Zealand: a call for standardisation.Somatostatin receptor scintigraphy might be useful for detecting skeleton abnormalities in patients with multiple myeloma and plasmacytomaInternational Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Nasopharyngeal amyloidosis: an unusual cause for epistaxis.
P2860
Q26740446-830CB183-6F28-4468-BF1D-B55AA4FC4AA3Q30833769-078428D5-7501-4DFB-A0C1-CDCE1C046C1CQ33294938-D0ACAC87-E28C-42B1-817B-270B7EEC47F4Q33322921-A7CBA31F-C930-4D6E-9670-056759DA5B7CQ33399416-C43A01F6-D313-4BE5-9721-AB93633E8EFBQ33400724-0057CFAF-682B-4B74-9085-D3F3FA5D231FQ33535489-66FE2E68-03D0-4828-945F-C92BDFE73BC0Q33541294-5CEA1AD8-B269-4BD9-B3D1-39FA5092E0B9Q33784183-115E5FB8-2400-4846-B549-BABBBD899E35Q33956039-B95CB1A2-1437-4CFB-AEC8-D681DF8BFA1EQ33973877-EB7E7409-622E-4D5A-9164-5E37C99E6FA2Q34090190-045DB0C1-BB77-47FA-AC3B-A8C243557B7AQ34316858-C950EA25-5D51-40EB-B929-BB393896667AQ34568939-E9B9C5EF-0D54-4776-83E9-6E780C0F4104Q34748502-C90AB34C-9394-4564-ADA4-E8F669CC72ABQ34758218-6D182D7F-DB2E-4A47-BE03-F311ED9712C4Q35483580-0AF3832D-32B2-4DC2-A9BF-67ED86461891Q35488351-20C6A71A-FD38-4088-BB53-A40B200E2618Q35802414-A852170C-E78C-46BB-87D6-2162853183F3Q35959247-B1559EBD-1292-4A43-A675-1A39CFC0CE02Q36088711-A10F4645-A8DC-4402-BA1C-584042BC741EQ36288045-9BF42447-D579-4258-BADD-180686E0556BQ36343449-9DD387F0-FAAE-4EC0-ADFF-C619A7E00644Q36382493-A1487638-AFC8-4B80-A89F-23E11C189E84Q36412591-110B40B5-5787-498F-B1BD-0F03907DD445Q36521862-B6601FCD-B01E-4008-8553-D834C69F56A8Q36570225-D9AA39C3-8ED6-4397-9361-DD9CFEA80812Q36778432-0211D719-587E-42C4-A8F7-9968F42FB00BQ36879132-05F38280-1BBE-43CB-B139-F93585F30F83Q36904977-35EAE69C-1DBD-4DB3-87B5-1997E086890AQ36985968-0269F8D4-EF2E-4B6D-88F4-CE6140448EA5Q37048573-FF45D8C7-04D0-44DB-A79F-5FE8A0C7F8F4Q37137157-5E5CEFF4-EC9E-4FDF-B81F-4768744FC442Q37183557-6137D4B4-7F5E-4BF2-8008-4F722B016D3DQ37246775-1F81D043-7771-45C2-A1DC-A9FC9A40C88EQ37271002-85F07FEF-FAF4-4B38-BFA0-BA2517A5A172Q37370047-FE92D85B-2D48-4DD8-B8BF-27F92061F747Q37469171-569F6BBE-1675-4B17-A055-B5E31EFABDA9Q37507513-D06610C2-6EAF-4D10-8B23-FEF1372ADBDEQ37519931-6F87CB1C-F380-4332-804C-8B153D1F5F6F
P2860
Guidelines on the diagnosis and management of multiple myeloma 2005.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Guidelines on the diagnosis and management of multiple myeloma 2005.
@en
Guidelines on the diagnosis and management of multiple myeloma 2005.
@nl
type
label
Guidelines on the diagnosis and management of multiple myeloma 2005.
@en
Guidelines on the diagnosis and management of multiple myeloma 2005.
@nl
prefLabel
Guidelines on the diagnosis and management of multiple myeloma 2005.
@en
Guidelines on the diagnosis and management of multiple myeloma 2005.
@nl
P2093
P2860
P1476
Guidelines on the diagnosis and management of multiple myeloma 2005.
@en
P2093
Alastair Smith
Diana Samson
Finn Wisloff
Nordic Myeloma Study Group
UK Myeloma Forum
P2860
P304
P356
10.1111/J.1365-2141.2005.05867.X
P407
P577
2006-02-01T00:00:00Z